文献速递肾癌与肾肿瘤

高危局限性肾细胞癌原发与复发肿瘤的基因组及转录组配对分析

Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma.
PubMed 文献 · Eur Urol · 2026-04-25

基于IMmotion010试验,对754例基线及80例复发肿瘤组织进行配对转录组(n=80)和基因组(n=52)分析。原发肿瘤以血管生成和小核仁RNA特征为主,复发灶上调增殖、脂肪酸合成及基质生物学特征;安慰剂复发者B细胞和巨噬细胞特征增加,阿替利珠单抗复发者MHC-I下调。

要点

  • 高危局限性肾细胞癌原发与复发肿瘤存在转录组差异。
  • 复发灶上调细胞增殖、脂肪酸合成和基质/成纤维细胞特征。
  • 阿替利珠单抗后复发者MHC-I下调,提示后续VEGF抑制可能合理。

核心结论

  • 高危局限性肾细胞癌原发与复发肿瘤在转录组和基因组上存在差异,复发后微环境特征改变。

研究设计与样本

  • IMmotion010随机试验中,收集基线肿瘤组织754例和复发时肿瘤组织80例,进行配对转录组(n=80)和基因组(n=52)分析。

主要发现

  • 原发肿瘤较已发表转移队列有更高比例的血管生成和小核仁RNA转录组特征,以及更低比例的T效应/增殖和基质/增殖特征。
  • 复发部位上调细胞增殖、脂肪酸合成和基质生物学(包括基质和成纤维细胞)相关特征。
  • 安慰剂治疗复发肿瘤B细胞和巨噬细胞特征增加,阿替利珠单抗治疗复发肿瘤MHC-I下调。

临床怎么用

  • 辅助免疫检查点抑制剂后复发者MHC-I下调,或可为后续转为VEGF抑制提供科学依据,但需进一步临床验证。

局限性

  • 研究结果需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Recurrence after nephrectomy in high-risk localized renal cell carcinoma is common, but the genomic and transcriptomic differences between primary and recurrent tumors are not well understood. In the IMmotion010 trial, patients were randomized to receive adjuvant atezolizumab versus placebo. Tumor tissue was collected at pre-treatment baseline (n = 754) and subsequently at the time of recurrence (n = 80). We performed matched transcriptomic (n = 80) and genomic (n = 52) analyses on primary versus recurrent samples. Using previously described transcriptomic classifications, resected primary tumors had a higher proportion of angiogenic and small nucleolar RNA transcriptomic signatures and lower proportion of T-effector/proliferative and stromal/proliferative signatures compared with published metastatic cohorts. Sites of recurrence exhibited upregulation of signatures related to cell proliferation, fatty acid synthesis, and stromal biology, including matrix and fibroblasts. Comparing treatment arms, tumors that recurred in placebo-treated patients demonstrated increased B cell and macrophage signatures, while tumors that recurred despite adjuvant atezolizumab showed downregulation of major histocompatibility complex (MHC)-I. Although requiring further clinical validation, the latter finding may substantiate scientifically a potential rationale for transitioning to vascular endothelial growth factor (VEGF)-inhibition after adjuvant checkpoint inhibition.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Xu W, Rini BI, Albiges L, et al. Comprehensive Genomic and Transcriptomic Characterization of Matched Primary and Recurrent Tumors in High-risk Localized Renal Cell Carcinoma. Eur Urol. 2026. PMID: 42036258. doi:10.1016/j.eururo.2026.03.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。